7/5/2013

An Australian hospital has cleared Prana Biotechnology's request to conduct a 12-month extension study of PBT2, the company's Alzheimer's disease drug candidate. PET imaging will be used to examine changes in the brains of Alzheimer's patients who have received PBT2 treatment for 12 months as part of the company's IMAGINE trial.

Related Summaries